KIORA PHARMACEUTICALS INC 8-K

What Happened
On May 8, 2026 Kiora Pharmaceuticals, Inc. announced financial results for the quarter ended March 31, 2026 and provided an update on its clinical development program. The company furnished a press release with those details as Exhibit 99.1 to its Form 8-K. The 8-K was signed by CFO Melissa Tosca.

Key Details

• Filing date: May 8, 2026 (Form 8-K, Item 2.02: Results of Operations and Financial Condition).
• Reporting period: quarter ended March 31, 2026.
• Disclosure: press release attached as Exhibit 99.1 (press release referenced in the filing).
• Authorized signature: Melissa Tosca, Chief Financial Officer.

Why It Matters
This 8-K signals Kiora has published its latest quarterly results and provided program updates—information that can affect near-term investor decisions and share valuation. The Form 8-K itself does not list numeric financials in its text; investors should read the attached press release (Exhibit 99.1) for specific figures (revenue, net loss, cash position) and details on clinical milestones or timelines that could serve as future catalysts.